Harnessing the Power of the Tumor Microenvironment with First-in-Class Therapies

In this Q&A, Purple Biotech’s CEO Gil Efron discusses the tumor microenvironment, Purple’s scientific approach, its two first-in-class clinical assets, NT219 and CM24, and the promise of its newly acquired trispecific antibody.

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: